Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Cancer Research UK
Servier
Actinogen Medical
Assistance Publique - HĂ´pitaux de Paris
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
St. Jude Children's Research Hospital
Hennepin Healthcare Research Institute
St. Jude Children's Research Hospital
Sun Yat-sen University
Cancer Research UK
Monash University
Monash University
Monash University
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Acacia Pharma Ltd
National University of Malaysia
Hospital Regional de Alta Especialidad del Bajio
Children's Cancer Group, China
Nektar Therapeutics
Ann & Robert H Lurie Children's Hospital of Chicago
Universität des Saarlandes
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Universitätsklinikum Hamburg-Eppendorf
Klinikum Bremen-Mitte, gGmbH
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Shanghai YingLi Pharmaceutical Co. Ltd.
University College, London
TG Therapeutics, Inc.
Monash University
Sohag University
Emergent BioSolutions
St. Anna Kinderkrebsforschung
Jazz Pharmaceuticals
Gruppo Italiano Trapianto di Midollo Osseo
Alexion Pharmaceuticals, Inc.
Medical College of Wisconsin
Goethe University
TG Therapeutics, Inc.
Nanfang Hospital, Southern Medical University
Fondazione Italiana Linfomi - ETS
ERYtech Pharma
Gilead Sciences
Roswell Park Cancer Institute
Kiadis Pharma
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia